David Shaywitz, MD, PhD

David Shaywitz, MD, PhD

Creator
0 followers

Physician/strategist; writes on tech x health, behavior change, and policy.

AI in Health: Management Push vs User‑Driven Adoption
SocialMay 21, 2026

AI in Health: Management Push vs User‑Driven Adoption

Fascinating recent contrasts involving application of AI to health+science: 1: Multiple convos re: AI+pharma, general emphasis is senior mgmt push, essentially "eat your brocolli" 2. @NEJM_AI pcast re: @EvidenceOpen - adoption is pulled by users b/c product=inherently compelling

By David Shaywitz, MD, PhD
AI and Nurse Practitioners Together Amplify Healthcare Potential
SocialMay 17, 2026

AI and Nurse Practitioners Together Amplify Healthcare Potential

Interesting, timely article on ascendancy of NPs; remarkable parallels (pro & con) w arguments around MDs and AI. MDs say a good doc is best; AI/NP champions say available AI/NP>fantasy of Marcus Welby. https://t.co/wZCH6QBL4y ofc, AI+NP=even more promising? @zakkohane

By David Shaywitz, MD, PhD
HHS Leader Undermines Science, Stifles Agency Function
SocialMay 11, 2026

HHS Leader Undermines Science, Stifles Agency Function

At a time when there's so much criticism around leads of FDA, NIH, etc, need to be clear what the core issue is: head of HHS who is effectively inimical to science. It's a preposterous situation. While it holds, essentially...

By David Shaywitz, MD, PhD
Balancing Satisficing and Sequential Optimization in Performance
SocialMay 10, 2026

Balancing Satisficing and Sequential Optimization in Performance

@DavidEpstein Loving your book, curious if u see any tension betw early emphasis on satisficing (vs optimizing/maximizing), & subsequent discussion of theory of constraints, where swimmer (eg) uses this approach to sequentially optimize all aspects of her performance @BStulberg

By David Shaywitz, MD, PhD
Align Corporate AI Initiatives with “AI for Good” Principles
SocialMay 10, 2026

Align Corporate AI Initiatives with “AI for Good” Principles

Short thead: discussion of AI implementation in organizations, in context of book I review this weekend in the Journal, "AI for Good" -> https://t.co/uQNiT6JpYH @emollick @zakkohane @JamesBessen @levie @PalantirTech @wolfejosh @ScottGottliebMD @bobkocher

By David Shaywitz, MD, PhD
New Column Highlights Pragmatic AI Implementation Over Apocalyptic Debate
SocialMay 10, 2026

New Column Highlights Pragmatic AI Implementation Over Apocalyptic Debate

1/ New @timmermanreport column focused not on whether AI will save or doom the world - which eschaton is likely to be immanentized – but rather on how pragmatic doers are trying to gainfully implement AI in a range of...

By David Shaywitz, MD, PhD
AI's Real-World Impact in Pharma and Medicine
SocialMay 9, 2026

AI's Real-World Impact in Pharma and Medicine

Just out-latest @timmermanreport post: AI in Practice: on the important, difficult work of getting AI to deliver-in pharma, medicine, & beyond. https://t.co/fuwuxubhrb Cited: @Loftus, @oziadias, @DeanKateBaicker, @EricTopol, @patricksmalone, @arjunmanrai, @zakkohane, @WSJBooks

By David Shaywitz, MD, PhD
Influencers Earn Money Through Brands, Virality, or Division
SocialMay 9, 2026

Influencers Earn Money Through Brands, Virality, or Division

The 3 routes to influencer $ (v.i.): 1. Brand deals/"human billboard," & usually beholden to (multiple) brands 2. Platform partners/desperate pursuit of virality, usu via clickbait/negative emotional arousal 3. Monetize audience/usually involves cultivating "us vs them" dynamic.

By David Shaywitz, MD, PhD
AI-Driven Method Creates Robust Clinical Trial Surrogate Markers
SocialMay 9, 2026

AI-Driven Method Creates Robust Clinical Trial Surrogate Markers

Super interesting via @oziadias & @DeanKateBaicker on an approach to generating robust surrogate markers, urgently needed but elusive, for clin trials, essentially via channeling the AI-enabled empiric analysis that I associate w PRS (cc @pnatarajanmd) https://t.co/FDP4Ym8ycC

By David Shaywitz, MD, PhD
AI Talent Shuns Pharma, Feeling Reduced to Code Writers
SocialMay 8, 2026

AI Talent Shuns Pharma, Feeling Reduced to Code Writers

Astute @endpts article on why rising AI talent not drawn to pharma; $ part, but key reason=“Pharma might just see us as people who write code or run models for them, and not really value for research." Mirror image of...

By David Shaywitz, MD, PhD
Creators' Notebooks Reveal the Messy Path to Greatness
SocialMay 8, 2026

Creators' Notebooks Reveal the Messy Path to Greatness

Fascinated by the way notebooks & diaries (while imperfect) can reveal so much about the way great works happens, and the way impactful creators go about their work. Classic eg: "Private Sci of Louis Pasteur." Another: Camus, as discussed @WSJBooks...

By David Shaywitz, MD, PhD
GLP‑1 Breakthrough Costs $500/Month, Limiting Access
SocialMay 8, 2026

GLP‑1 Breakthrough Costs $500/Month, Limiting Access

After catching my breath (unusual for GLP-1 story to discuss their costs approvingly), I suspect both that @continetti (not unusually) is likely directionally right (& I share enthusiasm for free market) - but - at $500/mo for transformative drug -...

By David Shaywitz, MD, PhD
David Shor: Premier Mentor for Evidence‑Based Political Data Science
SocialMay 6, 2026

David Shor: Premier Mentor for Evidence‑Based Political Data Science

I would add that *independent of political persuasion* if you're someone seeking to learn the thoughtful, evidence-based application to politics of cutting edge data science, ML etc, it's hard to contemplate a better mentor than @davidshor

By David Shaywitz, MD, PhD
Cutting Hyper‑palatable Food Access Could Curb Obesity
SocialMay 6, 2026

Cutting Hyper‑palatable Food Access Could Curb Obesity

New @juliaoftoronto reiterates key theme of her bk w @KevinH_PhD: key driver of obesity=ready availability of cal-dense hyperpalatable food around us; if this could be reduced, we might not need GLP-1s. Realistic to put genie back in bottle (for the...

By David Shaywitz, MD, PhD